Do you have a rare kidney disease
like FSGS, IgA Nephropathy,
or other Nephrotic Syndrome condition?
Let us help you find clinical trials and specialists.
1.
Share your diagnosis
To help us match you to clinical trials. Enter your zip/postal code to see trial sites in your area.
2.
Click "Am I a Fit?"
To get personalized results
3.
Click "I'm Interested"
On a specific trial location to connect directly with the study team for an appointment
1.
2.
3.
Share your diagnosis
To help us match you to clinical trials. Enter your zip/postal code to see trial sites in your area.
Click "Am I a Fit?"
To get personalized results
Click "I'm Interested"
On a specific trial location to connect directly with the study team for an appointment
Featured Trials
The EPPIK study will evaluate the investigational drug, sparsentan, for the treatment of selected rare kidney diseases. The investigational approach is to lower proteinuria levels with sparsentan and slow the loss of kidney function in children ages 2-17 with enrollment currently open to patients aged 2 to 7 years. Indications include: • IgA nephropathy (IgAN), also known as Berger’s disease • IgA vasculitis (IgAV), also known as Henoch-Schönlein purpura • Alport syndrome (AS).
See also the EPPIK Clinical Study for Children with FSGS and MCD.
The EPPIK study will evaluate the investigational drug, sparsentan, for the treatment of selected rare kidney diseases. The investigational approach is to lower proteinuria levels with sparsentan and slow the loss of kidney function in children ages 1-17 with enrollment currently open to patients 2 to 7 years. Indications include: • Focal segmental glomerulosclerosis (FSGS) • Minimal change disease (MCD) See also the EPPIK Clinical Study for Children with IgAN, IgAV, and Alport Syndrome.